HDAC9 and cancer: TSA was originally developed as a broad-spectrum HDAC inhibitor for anti-cancer therapy and has been associated with adverse effects such as gastrointestinal disturbances, hematological abnormalities and immunosuppression in animal models and early-phase clinical trials [30, 31].